Effect of intravenous iron (ferric derisomaltose) on haemoglobin and clinical events according to age in patients with heart failure and iron deficiency in a randomised trial (ironman)

被引：0

作者：

Squire, Iain ^{[1
]}

Cowburn, Peter ^{[2
]}

Lang, Ninian ^{[3
]}

Critoph, Chris ^{[4
]}

Schiff, Rebekah ^{[5
]}

Szwejkowski, Ben ^{[6
]}

Petrie, Mark ^{[7
]}

Kalra, Paul ^{[8
]}

Ford, Ian ^{[7
]}

Ray, Robin ^{[9
]}

Donnelly, Patrick ^{[10
]}

Clelland, John G. F. ^{[7
]}

Robertson, Michele ^{[7
]}

Thomson, Elizabeth ^{[7
]}

Banerjee, Prithwish ^{[11
]}

Nageh, Thuraia ^{[12
]}

机构：

[1] Glenfield Hosp, Dept Cardiovasc Sci, Cardiovasc Res Ctr, Leicester, Leics, England

[2] Univ Hosp Southampton, Southampton, Hants, England

[3] Univ Glasgow, Glasgow, Lanark, Scotland

[4] Univ Hosp Bournemouth, Bournemouth, Dorset, England

[5] Guys & St Thomas NHS Trust, London, England

[6] Ninewells Hosp & Med Sch, Dundee, Scotland

[7] Univ Glasgow, Glasgow, Lanark, Scotland

[8] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[9] St Georges Hosp NHS Trust, London, England

[10] Univ HF Leicester, Leicester, Leics, England

[11] Univ Hosp Coventry & Warwickshire, Coventry, W Midlands, England

[12] Mid & South Essex NHS Trust, Southend On Sea, Essex, England

来源：

HEART | 2023年 / 109卷

关键词：

IRONMAN; HEART FAILURE; IRON DEFICIENCY;

D O I：

10.1136/heartjnl-2023-BCS.134

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

134

引用

页码：A154 / A155

页数：2

共 50 条

[1] Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial
Sze, Shirley
Squire, Iain
Kalra, Paul R.
Cleland, John G.
Petrie, Mark C.
Kalra, Philip A.
Ahmed, Fozia
Banerjee, Prithwish
Boos, Christopher J.
Chapman, Callum
Cowburn, Peter James
Dixon, Lana
Duckett, Simon
Lane, Rebecca
Foley, Paul
Lang, Ninian N.
Lyons, Kristopher
Ray, Robin
Schiff, Rebekah
Thomson, Elizabeth A.
Robertson, Michele
Ford, Ian
IRONMAN Study Grp
HEART, 2025,
[2] Effects of ferric derisomaltose in heart failure with iron deficiency according to severity of renal dysfunction in the IRONMAN trial
Ahmed, F. Z.
Kalra, P. R.
Cleland, J. G. F.
Al-Mohammad, A.
Clarke, A. L.
Dixon, L.
Gupta, P.
Lane, R.
Leslie, S.
Lyons, K.
Walsh, J.
Wong, A.
Squire, I. B.
Ford, I.
Kalra, P. A.
EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 347 - 348
[3] Intravenous ferric derisomaltose for patients with heart failure: does iron heart translate into IRONMAN?
Vergallo, Rocco
Pedicino, Daniela
EUROPEAN HEART JOURNAL, 2023, 44 (14) : 1203 - 1204
[4] Effect of intravenous ferric derisomaltose in women compared to men with heart failure in the ironman randomised trial
Seed, Alison
Pellicori, Pierpalo
Kalra, Paul
Glover, Jason
Japp, Alan
Lane, Rebecca
Ludman, Andrew
Cooke, Justin
Al-Mohammad, Abdallah
Robertson, Michele
Chong, Victor
Clelland, John G. F.
Ford, Ian
HEART, 2023, 109 : A169 - A170
[5] Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial
Cleland, John G. F.
Kalra, Philip A.
Pellicori, Pierpaolo
Graham, Fraser J.
Foley, Paul W. X.
Squire, Iain B.
Cowburn, Peter J.
Seed, Alison
Clark, Andrew L.
Szwejkowski, Ben
Banerjee, Prithwish
Cooke, Justin
Francis, Mark
Clifford, Piers
Wong, Aaron
Petrie, Colin
McMurray, John J., V
Thomson, Elizabeth A.
Wetherall, Kirsty
Robertson, Michele
Ford, Ian
Kalra, Paul R.
EUROPEAN HEART JOURNAL, 2024, 45 (16) : 1410 - 1426
[6] Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN) : an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
Kalra, Paul R.
Cleland, John G. F.
Petrie, Mark C.
Thomson, Elizabeth A.
Kalra, Philip A.
Squire, Iain B.
Ahmed, Fozia Z.
Al-Mohammad, Abdallah
Cowburn, Peter J.
Foley, Paul W. X.
Graham, Fraser J.
Japp, Alan G.
Lane, Rebecca E.
Lang, Ninian N.
Ludman, Andrew J.
Macdougall, Iain C.
Pellicori, Pierpaolo
Ray, Robin
Robertson, Michele
Seed, Alison
Ford, Ian
LANCET, 2022, 400 (10369): : 2199 - 2209
[7] Infection risk with ferric derisomaltose compared to standard of care in patients with heart failure and iron deficiency: a prespecified analysis of the IRONMAN trial
Kalra, P.
Cleland, J. G. F.
Foley, P. W. X.
Petrie, M.
Thomson, E.
Kalra, P. A.
Squire, I. B.
Graham, F.
Pellicori, P.
Macdougall, I.
Robertson, M.
Clark, A.
Lane, R. E.
Ahmed, F. Z.
Ford, I.
EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 259 - 259
[8] Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic - insights from the IRONMAN trial
Lee, Matthew M. Y.
Petrie, Mark C.
Cleland, John G. F.
Donnelly, Patrick
Francis, Mark
Hannah, Andrew
Japp, Alan G.
Labinjoh, Catherine
Lang, Ninian N.
Manisty, Charlotte
Petrie, Colin J.
Piper, Susan E.
Williams, Simon G.
Ford, Ian
Kalra, Paul R.
EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (10) : 2293 - 2295
[9] Effect of intravenous ferric derisomaltose on outcomes in heart failure with or without ischaemic heart disease in the IRONMAN trial
Ludman, A. J.
Cleland, J. G. F.
Ford, I.
Graham, F.
Petrie, M.
Foley, P.
Chong, V.
Schiff, R.
Nageh, T.
Glover, J.
Spencer, C.
Matthews, I.
Boos, C.
Campbell, P.
Kalra, P. M.
EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 222 - 222
[10] Risk of infection with ferric derisomaltose compared to standard of care in patients with heart failure and iron deficiency in the uk: a prespecified analysis of the ironman trial
Foley, Paul
Kalra, Paul
Lane, Rebecca
Petrie, Mark
Cowburn, Peter
Thomson, Elizabeth
Critoph, Christopher
Ray, Robin
Robertson, Michele
Clark, Andrew
Ford, Ian
Clelland, John G. F.
Squire, Iain
HEART, 2023, 109 : A156 - A156

← 1 2 3 4 5 →